2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatients
2020
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCystadenocarcinoma, SerousCytoreduction Surgical ProceduresDrug Administration ScheduleEndometrial NeoplasmsEndometriumFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProgression-Free SurvivalReceptor, ErbB-2Survival AnalysisTrastuzumabConceptsProgression-free survivalRandomized phase II trialPhase II trialOverall survivalHER2/neuStage IIICarboplatin-paclitaxelII trialRecurrent diseaseControl armSurvival analysisRecurrent uterine serous carcinomaCarboplatin/paclitaxelUterine serous carcinomaOverall survival analysisEvaluable patientsEligible patientsPrimary endpointSecondary endpointsEndometrial cancerAggressive variantSerous carcinomaPrimary treatmentSurvival medianPatients
2019
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatment
2018
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors
Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAzepinesBRCA1 ProteinBRCA2 ProteinCell Line, TumorClass I Phosphatidylinositol 3-KinasesFemaleHumansMiceMutationNeoplasm MetastasisNeoplasm Recurrence, LocalOvarian NeoplasmsProteinsProto-Oncogene Proteins c-mycTriazolesTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsOvarian cancerWhole-exome sequencingC-myc amplificationRecurrent tumorsPrimary tumorBET inhibitorsChemotherapy-resistant diseaseRecurrent ovarian cancerLethal gynecologic malignancyBilateral ovarian cancerChemotherapy-resistant tumorsPrimary metastatic tumorsMutational landscapeSomatic mutationsFresh-frozen tumorsGynecologic malignanciesMetastatic tumorsPrimary cell linesC-MYC gainPIK3CA amplificationTranscoelomic metastasisTherapeutic targetPatientsMetastatic abilityTumors
2016
Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study
Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.Peer-Reviewed Original ResearchConceptsPositive skin testsHypersensitivity reactionsDesensitization protocolSkin testCarboplatin infusionLife-threatening hypersensitivity reactionSingle-institution retrospective studyCarboplatin desensitization protocolPrior hypersensitivity reactionMajority of patientsCarboplatin hypersensitivity reactionsCarboplatin hypersensitivityPulmonary hypertensionAdverse eventsRetrospective reviewRetrospective studyGynecologic cancerGrade 0Patient deathRisk factorsCardiac conditionsPatientsLarger studyInfusionAgeIncidental injury and repair of obturator nerve during laparoscopic pelvic lymphadenectomy
Menderes G, Vilardo N, Schwab CL, Azodi M. Incidental injury and repair of obturator nerve during laparoscopic pelvic lymphadenectomy. Gynecologic Oncology 2016, 142: 208. PMID: 27234143, DOI: 10.1016/j.ygyno.2016.05.023.Peer-Reviewed Original ResearchConceptsObturator nervePelvic lymphadenectomyTension-free anastomosisIncidental injuryLaparoscopic repairPostoperative day oneLaparoscopic pelvic lymphadenectomyDistal cut endEnd coaptationResidual neuropathyLaparoscopic stagingNeurologic deficitsEndometrial adenocarcinomaGynecologic surgeryLeft thighNeurologic deficiencyAdductor functionLymphadenectomyNerve edgesNerveGynecologic surgeonsFree anastomosisImmediate repairPatientsPolypropylene sutureRobot-Assisted Abdominal Cerclage During Pregnancy
Zeybek B, Hill A, Menderes G, Borahay MA, Azodi M, Kilic GS. Robot-Assisted Abdominal Cerclage During Pregnancy. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2016, 20: e2016.00072. PMID: 27904309, PMCID: PMC5118107, DOI: 10.4293/jsls.2016.00072.Peer-Reviewed Original ResearchConceptsAbdominal cerclageMedian gestational ageMedian ageCase seriesGestational ageSystematic reviewMedian operating timePostoperative day 1Time of procedureRetrospective case studyCervical insufficiencyTransabdominal cerclageVaginal cerclagePreterm laborCervical lacerationPreterm birthTransvaginal cerclageBlood lossPrevious pregnancyPremature ruptureInfant morbidityPrevious dilatationMajor indicationCerclagePatients
2014
Robotic-assisted abdominal cerclage: a case report and literature review
Menderes G, Clark L, Azodi M. Robotic-assisted abdominal cerclage: a case report and literature review. Journal Of Robotic Surgery 2014, 8: 195-200. PMID: 27637677, DOI: 10.1007/s11701-014-0462-3.Peer-Reviewed Original ResearchAbdominal cerclage placementCerclage placementAbdominal cerclageUltrasound guidanceTransabdominal cerclage placementUncomplicated antenatal coursePrimary cesarean sectionMain outcome measuresRobotic assistanceCervical insufficiencyAntenatal courseCervical lengthPrior pregnancyCesarean sectionPara 0Term deliveryCase reportTeaching hospitalGravid uterusNeonatal survivalOutcome measuresCerclagePatientsRobotic surgeonsWeeks
2013
Robotic Repair of Uterine Dehiscence
La Rosa MF, McCarthy S, Richter C, Azodi M. Robotic Repair of Uterine Dehiscence. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2013, 17: 156-160. PMID: 23743391, PMCID: PMC3662738, DOI: 10.4293/108680812x13517013317996.Peer-Reviewed Original ResearchConceptsUterine scar dehiscenceScar dehiscenceCesarean scarCesarean deliveryRobotic repairMultiple cesarean deliveriesSuccessful robotic repairNumber of complicationsPersistent vaginalUterine dehiscenceCommon complicationMore patientsTreatment guidelinesRobotic surgeryDehiscenceComplicationsFurther studiesPatientsSignificant increaseMonthsRepairScarDeliverySurgeryVaginal
2012
Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients
Gallo T, Kashani S, Patel DA, Elsahwi K, Silasi DA, Azodi M. Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2012, 16: 421-427. PMID: 23318068, PMCID: PMC3535794, DOI: 10.4293/108680812x13462882735890.Peer-Reviewed Original ResearchConceptsBody mass indexObese patientsLaparoscopic hysterectomyBMI groupsRobotic-assisted laparoscopic hysterectomyCommunity teaching hospitalLength of stayAssisted Laparoscopic HysterectomyNonobese patientsPerioperative outcomesPatient characteristicsPatient demographicsBlood lossOperative outcomesSurgical indicationsOperative timeRetrospective reviewMass indexRobotic hysterectomySurgical outcomesMalignant conditionsTeaching hospitalCase of womenHysterectomyPatients
2011
A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study
El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study. Gynecologic Oncology 2011, 124: 471-473. PMID: 22014628, DOI: 10.1016/j.ygyno.2011.09.029.Peer-Reviewed Original ResearchConceptsWithdrawal of carePercent of respondentsGynecologic oncologistsLife discussionsAdvanced-stage cancerProgression of diseaseYears of ageFirst recurrenceMajor surgeryPatient ageHalf of respondentsStage cancerMedical statusResponse rateTumor sitePatientsOncologistsPilot studyPilot surveyHealth insuranceInitial responseSurvey MonkeyAgeSocial supportCareHer2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCulture Media, ConditionedFemaleFlow CytometryGenes, erbB-2HumansImmunohistochemistryImmunotherapyIn Situ Hybridization, FluorescenceMiddle AgedReal-Time Polymerase Chain ReactionTrastuzumabUterine NeoplasmsConceptsAntibody-dependent cell-mediated cytotoxicityTrastuzumab-mediated antibody-dependent cell-mediated cytotoxicityUSC cell linesHER2/neu expressionUSC patientsNeu expressionHER2/ECD levelsCell linesUterine serous carcinoma cell linesCell-mediated cytotoxicityUterine serous carcinomaChromium release assaysHER2/neuFISH-positive tumorsC-erbB2 gene amplificationTrastuzumab-induced cytotoxicityNeu tumorsHealthy womenSerous carcinomaCarcinoma cell linesReal-time PCRTherapeutic effectC-erbB2 genePatients
2010
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience
Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.Peer-Reviewed Original ResearchConceptsVulvar Paget's diseasePaget's diseaseNeu overexpressionOutcome dataHER-2/neu expressionHER-2/neuEfficacy of trastuzumabExtensive reconstructive proceduresHigh recurrence rateMedical record searchInteresting treatment optionSurgical treatmentRecurrence rateTreatment optionsNeu expressionClinical trialsReconstructive proceduresTissue microarrayPatientsRecord searchTumor samplesYale experienceDiseaseNeuStaining results
2007
Carcinosarcoma of the ovary
SILASI D, ILLUZZI JL, KELLY MG, RUTHERFORD TJ, MOR G, AZODI M, SCHWARTZ PE. Carcinosarcoma of the ovary. International Journal Of Gynecological Cancer 2007, 18: 22-29. PMID: 17451459, DOI: 10.1111/j.1525-1438.2007.00948.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinosarcomaChemotherapy, AdjuvantCisplatinCombined Modality TherapyDisease-Free SurvivalFemaleHumansIfosfamideMiddle AgedOvarian NeoplasmsPaclitaxelRegistriesRetrospective StudiesSurvival RateTreatment OutcomeConceptsProgression-free intervalMedian progression-free intervalAdvanced stage diseaseMedian survivalOptimal cytoreductionOvarian carcinosarcomaStage diseaseTaxol groupEffective cytotoxic regimenFirst-line cisplatinFirst-line chemotherapyCombination of carboplatinEpithelial ovarian cancerCytotoxic regimenIfosfamide groupAdjuvant cisplatinEntire cohortMedical recordsOvarian cancerCytoreductionPatientsSurvival rateCarcinosarcomaCarboplatinCisplatin
2005
Adenoid cystic carcinoma of the cervix
Koyfman SA, Abidi A, Ravichandran P, Higgins SA, Azodi M. Adenoid cystic carcinoma of the cervix. Gynecologic Oncology 2005, 99: 477-480. PMID: 16139349, DOI: 10.1016/j.ygyno.2005.06.063.Peer-Reviewed Original ResearchConceptsCystic carcinomaStage IBHistologic featuresAggressive local therapyType III hysterectomyVaginal cuff radiationEvidence of diseaseStandardized treatment protocolSquamous cell carcinomaExternal beam radiotherapyLocal therapyAggressive neoplasmCell carcinomaTreatment protocolBeam radiotherapyHigh riskCervixCarcinomaAsian femalesPatientsIBHysterectomyRecurrenceNeoplasmsRadiotherapy